Nucleic Acid Testing Market : Global Industry Analysis and Opportunity Assessment, 2036

How big is the Nucleic Acid Testing Market in 2026?

USD 4.4 billion in 2026, reaching USD 6.9 billion by 2036 at a 4.6% CAGR

The nucleic acid testing market is estimated at USD 4.4 billion in 2026 and is forecast to reach USD 6.9 billion by 2036 at a 4.6% CAGR. Kits accounts for 57.0% of product revenue in 2026, while Infectious Diseases leads indication at 58.0%. Demand is shaped by buyers consolidating purchases around the kits category to control cost and qualification effort.

Volume builds through healthcare buyers standardizing specifications and retiring older kits installations over time. Adoption is increasing due to procurement teams favoring suppliers that reduce switching cost and shorten qualification. The fastest expansion sits in India at 9.3% CAGR, followed by China at 8.2%, where buying centers prioritize Ayushman Bharat coverage expansion.

Summary of the Nucleic Acid Testing Market

Market Signal	Commercial Impact
Demand and Growth Drivers	Recurring replacement demand and high switching costs keep kits procurement durable. Kits demand is reinforced as hospital replace aging units and add capacity, keeping product procurement recurring rather than one-off. Ayushman Bharat coverage expansion in India pulls forward purchases of infectious diseases, the fastest-qualifying specification for new sites. Switching cost favors incumbents: buyers that standardize on a kits platform avoid requalification, slowing entry for substitutes.
Product and Segment View	Kits and Infectious Diseases lead their respective segments in 2026. Kits is projected to hold 57.0% of product revenue in 2026, reflecting established buyer familiarity and supply availability. Infectious Diseases leads the indication category at 58.0% as buyers standardize specifications across sites. Hospital anchors the end user category, indicating where incremental adoption concentrates.
Geography and Competitive Outlook	India and China are expected to remain the key growth markets, with Danaher Corporation and Thermo Fisher Scientific Inc. leading competition. India records the fastest growth at 9.3% CAGR, supported by Ayushman Bharat coverage expansion. China follows at 8.2% CAGR, where volume-based procurement (VBP) tenders sustains procurement. Danaher Corporation and Thermo Fisher Scientific Inc. compete on supply depth and qualification support; service coverage is a further competitive lever.
Analyst Perspective	Buyers now judge kits on performance and total cost of ownership, not headline price. The nucleic acid testing market is shifting from fragmented buying toward consolidated supplier relationships as infectious diseases buyers weigh total cost of ownership over list price. Purchasers judge kits on qualification effort and lifecycle support. Suppliers that lower qualification friction for kits and keep infectious diseases specifications interoperable across buyer sites should secure the most durable procurement relationships over the forecast period. - Anurag Sharma, Principal Consultant at Future Market Insights

Why is the Nucleic Acid Testing Market growing?

Rising Kits and Infectious Diseases demand across healthcare end users

• Sustained procurement of kits is shaped by replacement cycles and capacity additions among healthcare buyers in both established and emerging markets.
• India leads growth at 9.3% CAGR, supported by Ayushman Bharat coverage expansion and private tertiary-care investment in metro hospitals.
• Infectious Diseases holds 58.0% of indication revenue, indicating where standardization is concentrating buyer spend.

Demand is shaped by buyers seeking consistent kits supply across multiple sites while limiting requalification. Adoption is increasing due to the operational cost of switching suppliers, which favors incumbents with broad product coverage and responsive service.

How is the Nucleic Acid Testing Market segmented?

By Product, Indication, End User and Application

• Kits leads the product category with 57.0% share in 2026 on the strength of buyer familiarity and supply availability.
• Infectious Diseases leads the indication category with 58.0% share as specifications standardize across buyer sites.
• Hospital anchors the end user category, marking where incremental volume is consolidating.

Why does Kits lead the Nucleic Acid Testing Market?

• Kits is expected to hold 57.0% of product revenue in 2026 because buyers retain it for predictable performance and lower requalification effort.
• Within it, Extraction Kits and Amplification Kits carry the bulk of specified demand.

How big is the Infectious Diseases segment in the Nucleic Acid Testing Market?

About 58.0% share, led by Infectious Diseases

• Infectious Diseases is forecast to hold 58.0% of indication revenue in 2026.
• Demand is supported where buyers standardize indication specifications to simplify sourcing.

Which end user leads the market?

• Hospital accounts for 30.0% share in 2026, the largest within end user.

How do the remaining segments shape the Nucleic Acid Testing Market?

• By application, Infectious Disease Testing is the leading category in 2026, with Viral Infection Testing and Bacterial Infection Testing taking most specified volume.

What drives and restrains the Nucleic Acid Testing Market?

Driven by kits replacement demand; restrained by qualification and cost barriers

Recurring product procurement supports expansion, while upfront cost and certification effort limit faster adoption among smaller buyers.

• Driver: Hospital sustain kits demand through replacement and capacity additions, keeping procurement recurring across the forecast period.
• Restraint: Certification and requalification effort for new product specifications slows substitution, particularly for smaller buyers with limited engineering capacity.
• Opportunity: Suppliers offering infectious diseases configurations that drop into existing workflows can widen adoption without full replacement.

Demand is shaped by buyers protecting continuity of supply, which rewards incumbents with broad product portfolios. Pricing remains influenced by input cost and the depth of qualified alternatives.

Supply is constrained by the concentration of qualified kits sources, so buyers value second-source options and responsive service over headline price alone.

Which factors support expansion in the Nucleic Acid Testing Market?

Replacement demand, standardization, and service coverage support market value

• Market value is supported by kits replacement purchases before aftermarket and service revenue accrues.
• Supplier pricing reflects product performance and availability before service coverage affects renewal demand.
• Buyers compare qualification time and support response before committing to multi-site standardization on infectious diseases.

Which countries are growing fastest in the Nucleic Acid Testing Market?

India 9.3%, China 8.2%, Germany 2.7%, USA 2.2%, Brazil 1.5% through 2036

Country	CAGR
India	9.3%
China	8.2%
Germany	2.7%
USA	2.2%
Brazil	1.5%

Source: FMI's proprietary forecasting model and primary research

How do country-level CAGRs compare in the Nucleic Acid Testing Market?

Country growth in the Nucleic Acid Testing Market is expected to vary through 2036, with India at 9.3%, China at 8.2%, Germany at 2.7%, USA at 2.2%, and Brazil at 1.5%. India is projected to grow fastest among the profiled countries and Brazil the slowest. Higher-growth markets are shaped more by new demand formation, while established markets weigh documented performance and supply continuity before account expansion.

• India is projected at 9.3% CAGR through 2036. India's trajectory is set less by price than by Ayushman Bharat coverage expansion. Buyers there judge kits on qualification effort and continuity of supply. Buyers cite Ayushman Bharat coverage expansion as the reason infectious diseases budgets are released ahead of schedule. Private tertiary-care investment in metro hospitals underwrites multi-year demand visibility rather than spot purchasing.
• China is projected at 8.2% CAGR through 2036. China demand rests on volume-based procurement (VBP) tenders, with domestic device manufacturing under import-substitution policy adding a second pillar of support. Buyers there judge kits on qualification effort and continuity of supply. Volume-based procurement (VBP) tenders is the primary pull, converting policy intent into firm infectious diseases orders. Where domestic device manufacturing under import-substitution policy applies, specification activity concentrates in the Yangtze River Delta and Pearl River Delta.
• Germany is projected at 2.7% CAGR through 2036. Germany demand rests on EU MDR re-certification cycles, with statutory health insurance (GKV) reimbursement review adding a second pillar of support. Buyers there judge kits on qualification effort and continuity of supply. EU MDR re-certification cycles is the primary pull, converting policy intent into firm infectious diseases orders. Germany's exposure to statutory health insurance (GKV) reimbursement review keeps replacement and expansion spending firm.
• USA is projected at 2.2% CAGR through 2036. FDA clearance pathways and CMS reimbursement codes and IRA drug-pricing pressure on integrated providers together shape how USA buyers plan procurement. Buyers there judge kits on qualification effort and continuity of supply. FDA clearance pathways and CMS reimbursement codes is the primary pull, converting policy intent into firm infectious diseases orders. USA's exposure to IRA drug-pricing pressure on integrated providers keeps replacement and expansion spending firm.
• Brazil is projected at 1.5% CAGR through 2036. In Brazil, SUS public procurement volumes is the structural driver buyers organize around. Buyers there judge kits on qualification effort and continuity of supply. SUS public procurement volumes widens the qualified buyer base for infectious diseases beyond the largest accounts. ANVISA registration requirements is the primary pull, converting policy intent into firm infectious diseases orders.

Who are the leading companies in the Nucleic Acid Testing Market?

Danaher Corporation, Thermo Fisher Scientific Inc., Abbott Laboratories, Inc, Illumina, Inc and Merck KGaA

Danaher Corporation and Thermo Fisher Scientific Inc. compete through supply depth and qualification support across healthcare buyers. Abbott Laboratories, Inc maintains position through portfolio breadth, while service coverage and lead-time reliability are further competitive levers.

Buyers compare suppliers on qualification time, second-source availability, and support response. Larger buyers favor vendors that standardize kits across sites; smaller buyers weigh distributor access and local service.

Who are the key players in the Nucleic Acid Testing Market?

Key global companies leading the market include:

• Danaher Corporation, Thermo Fisher Scientific Inc., Abbott Laboratories, Inc, Illumina, Inc and Merck KGaA maintain leading positions through established manufacturing, portfolio breadth, and direct procurement relationships.
• Qiagen, F. Hoffmann-La Roche Ltd, Agilent Technologies and Becton, Dickinson and Company compete through specialized configurations, competitive pricing, and localized distribution in high-growth markets.
• Bio-Rad Laboratories, Inc. and Others target underserved applications and regional markets to establish initial procurement positions.

How do top Nucleic Acid Testing Market companies compare?

Danaher Corporation and Thermo Fisher Scientific Inc. lead on scale; Abbott Laboratories, Inc also has a global footprint, while Illumina, Inc and Merck KGaA are more regionally concentrated.

Company	Portfolio Breadth	Qualification Depth	Supply Scale	Geographic Footprint
Danaher Corporation	High	High	Strong	Global
Thermo Fisher Scientific Inc.	High	High	Strong	Global
Abbott Laboratories, Inc	Medium	Medium	Moderate	Global
Illumina, Inc	High	Medium	Moderate	Regional
Merck KGaA	Medium	Medium	Moderate	Regional

Source: Future Market Insights competitive analysis, 2026.

Key Players in the Nucleic Acid Testing Market

Device and Equipment Manufacturers

• Danaher Corporation
• Illumina, Inc
• F. Hoffmann-La Roche Ltd
• Bio-Rad Laboratories, Inc.

Consumable and Specialty Suppliers

• Thermo Fisher Scientific Inc.
• Merck KGaA
• Agilent Technologies
• Others

Emerging and Regional Providers

• Abbott Laboratories, Inc
• Qiagen
• Becton, Dickinson and Company

Nucleic Acid Testing Market - Scope & Definition

Attribute	Detail
Market Definition	Products and solutions within the nucleic acid testing market spanning Product, Indication and End User categories
Key Segments Covered	Kits, Infectious Diseases and Hospital and related healthcare applications
Applications Covered	Infectious Disease Testing, Blood Screening, Oncology Testing and Genetic Testing
End-Use Industries	Hospital, Pathology Laboratory, Research Institute and Clinics
Inclusions	Commercially sold product, indication, and associated configurations
Exclusions	Custom one-off systems, standalone services, and raw inputs outside the nucleic acid testing market boundary

Nucleic Acid Testing Market - Research Methodology

Method	Description
Primary Research	FMI analyst interviews with healthcare suppliers, distributors, and procurement teams across major markets
Desk Research	Review of official activity data, regulatory releases, company disclosures, and production statistics
Market Sizing & Forecasting	Bottom-up sizing using segment revenue, adoption rates, replacement demand, and country-level activity
Data Validation	Cross-verification against public evidence, supplier portfolios, and official indicators

What does the Nucleic Acid Testing Market report cover?

2021 to 2025 history and 2026 to 2036 forecasts across all segments and 30+ countries

Parameter	Details
Forecast period	2026 to 2036
Historical period	2021 to 2025
Quantitative unit	Revenue in USD billion
By Product	Kits, Consumables, Instruments, Software and Services
By Indication	Infectious Diseases, Cancer, Forensic Testing and Others
By End User	Hospital, Pathology Laboratory, Research Institute, Clinics, Diagnostic Laboratories and Blood Banks
By Application	Infectious Disease Testing, Blood Screening, Oncology Testing, Genetic Testing and Transplant Diagnostics
Regions covered	North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, Middle East and Africa
Countries covered	USA, India, China, Germany, Brazil
Key companies profiled	Danaher Corporation, Thermo Fisher Scientific Inc., Abbott Laboratories, Inc, Illumina, Inc and Merck KGaA
Approach	Bottom-up segment-boundary approach using adoption, replacement demand, and supplier disclosures

Market Segmentation Analysis

Nucleic Acid Testing Market Segmented by Product:

• Kits
  • Extraction Kits
  • Amplification Kits
  • Detection Kits
• Consumables
• Instruments
  • Polymerase Chain Reaction Systems
  • Isothermal Amplification Systems
  • Sequencing Systems
• Software
  • Data Analysis Software
  • Result Interpretation Software
• Services
  • Diagnostic Testing Services
  • Laboratory Services

Nucleic Acid Testing Market Segmented by Indication:

• Infectious Diseases
• Cancer
• Forensic Testing
• Others

Nucleic Acid Testing Market Segmented by End User:

• Hospital
  • Public Hospitals
  • Private Hospitals
• Pathology Laboratory
• Research Institute
• Clinics
• Diagnostic Laboratories
  • Reference Laboratories
  • Independent Laboratories
• Blood Banks
  • Collection Centers
  • Processing Centers
• Academic and Research Institutes
  • Universities
  • Research Organizations
• Pharmaceutical and Biotechnology Companies
  • Drug Development
  • Clinical Trials

Nucleic Acid Testing Market Segmented by Application:

• Infectious Disease Testing
  • Viral Infection Testing
  • Bacterial Infection Testing
• Blood Screening
  • Donor Screening
  • Transfusion Safety Testing
• Oncology Testing
  • Cancer Detection
  • Genetic Mutation Analysis
• Genetic Testing
  • Inherited Disease Testing
  • Prenatal Testing
• Transplant Diagnostics
  • Histocompatibility Testing
  • Organ Matching

Nucleic Acid Testing Market by Region:

• North America
  • USA
  • Canada
  • Mexico
• Latin America
  • Brazil
  • Chile
  • Rest of Latin America
• Western Europe
  • Germany
  • UK
  • Italy
  • Spain
  • France
  • Nordic
  • BENELUX
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • Hungary
  • Balkan & Baltic
  • Rest of Eastern Europe
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia & New Zealand
  • Rest of South Asia and Pacific
• Middle East & Africa
  • Kingdom of Saudi Arabia
  • Other GCC Countries
  • Türkiye
  • South Africa
  • Other African Union
  • Rest of Middle East & Africa

Research Sources and Bibliography

• World Bank. (2026, March). World development indicators database.
• International Trade Centre. (2025, November). Trade statistics for international business development.
• OECD. (2026, February). Economic outlook and industry statistics.
• World Health Organization. (2025, December). Global health observatory data repository.
• USA Food and Drug Administration. (2026, January). Medical device databases.

This bibliography is provided for reader reference and is not exhaustive.

This Report Answers

• Market size estimates for 2026 and forecasts through 2036 for the nucleic acid testing market.
• Segment demand across product and indication with leading sub-segment shares.
• Country-level growth analysis covering USA, India, China, Germany and other markets.
• Company positioning across Danaher Corporation, Thermo Fisher Scientific Inc. and Abbott Laboratories, Inc and regional players.
• Assessment of drivers and restraints with procurement patterns across end-use buyers.